LY2886721

LY2886721 is an ß-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of ß-amyloid. LY2886721 inhibits recombinant hBACE1 with an IC50 of 20 nM. In cellular assays, LY2886721 inhibits Abeta with an IC50 range of 10-19 nM. LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid. Oral administration of LY2886721 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99 and sAPPbeta. LY2886721 is currently in a Phase II clinical trial in patients with Mild Cognitive Impairment.